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Abstract 
The aim of this study was to predict which 
Child-A cirrhotic patients would not have 
oesophageal varices at endoscopy.  
This is a retrospective study that reviewed 59 
Child-A cirrhotic patients under the care of a 
gastroenterology firm. All gastroscopy reports (97 
episodes in total) undergone by these patients were 
analysed. Patients were classified into 3 groups 
namely absent varices (AV) group: no oesophageal 
varices seen at endoscopy, small varices (SV) 
group: small oesophageal varices seen, banded 
varices (BV) group: moderate/large oesophageal 
varices requiring banding. In this study the varices 
were graded as per UK guidelines that is small 
varices being ones which collapse to inflation of the 
oesophagus with air, moderate varices do not 
collapse and large varices occlude the lumen.1 
Patient demographics, a platelet count and spleen 
size on imaging at the time of endoscopy were also 
noted. Statistical differences between the 3 groups 
were then analysed using ANOVA. 
Our results showed that most of the patients 
were middle aged males. Furthermore, there was a 
statistically significant difference in platelet count 
and spleen size between the three groups (p values: 
0.008 and 0.035 respectively).  A noteworthy 
finding was that none of the patients who required 
banding had a normal spleen size (spleen < 12 cm). 
Having said this, due to considerable overlap 
between the three groups, further recommendations 
could not be proposed.  
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Background 
Despite recent advances, oesophageal variceal 
bleeding in cirrhosis is still associated with 10-20% 
mortality at 6 weeks.1 Furthermore, in 35-90% of 
patients rebleeding occurs after spontaneous 
haemostasis (approximately 40% of rebleeding 
episodes occurring within the first 5 days).2 Once 
cirrhosis is diagnosed a gastroscopy is 
recommended to check for oesophageal varices in 
most cases.3 If oesophageal varices are present, 
treatment is required to prevent variceal bleeding 
(primary prophylaxis of variceal haemorrhage).4 
The recommended treatment is with non-selective 
beta blockers (NSBB) for patients with small 
varices and either NSBB or variceal banding if 
medium to large varices are present.1 Splenomegaly 
and consumptive thrombocytopenia are recognized 
complications of significant portal hypertension 
secondary to cirrhosis5 and potential indices for 
indirect diagnosis of oesophageal varices.6  
Aim 
Oesophageal varices are a major complication 
of portal hypertension and occur in 30-70% of 
cirrhotics.7 Is it possible to predict which cirrhotic 
patients will have oesophageal varices requiring 
treatment before performing a gastroscopy? 
Method 
This is a retrospective study looking at all the 
gastroscopy reports of Child-A cirrhotic patients 
under the care of a single 
gastroenterology/hepatology firm performed in 
2015 (see table 1 for population demographics).  
The diagnosis of cirrhosis was in most cases based 
on imaging studies as shear wave elastography has 
only recently been introduced locally. The aetiology 
of liver cirrhosis included autoimmune liver 
conditions, alcoholic liver disease, chronic viral 
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hepatitis and non-alcoholic steatohepatitis. Once a 
patient was recruited their previous endoscopies 
were also retrieved and matched with their Child- 
Pugh score at the time (see table 2). Platelet 
counts and spleen size as measured on imaging 
(US/CT/MRI) within three months of endoscopy 
were also recorded. For the purposes of the study a 
normal sized spleen is one which is less than 12 cm. 
During data collection whenever splenomegaly was 
noted on imaging but no precise measurement was 
given, a spleen size of 12 cm was allocated. 
Conversely a normal spleen with no precise 
measurement was given a value of 11 cm.8 The 
gastroscopy report was used to determine whether 
varices were present. If present and banding was 
performed this was also recorded. Once 
oesophageal banding was performed further 
endoscopies to control variceal size were excluded 
from the study since the question of prediction is no 
longer relevant in these patients. Patients with a 
previous splenectomy or who were suffering from 
myeloproliferative conditions (which often effects 
spleen size and platelet counts) were excluded from 
the study. Patients with early hepatocellular 
carcinoma (within the Milan transplant criteria)9 
were not excluded from the study as it was felt that 
early cancer would not contribute significantly to 
portal hypertension. ANOVA statistical analysis 
was used to measure significant differences 
between groups regarding platelet count and spleen 
size.  
 
Results 
A total number of 59 patients undergoing 97 
gastroscopies (episodes) between 2008 and 2015 
were included in the study. The cases were divided 
into 3 groups; absent varices (AV) group: no 
varices seen at endoscopy, small varices (SV) 
group: small varices not requiring banding and 
banded varices (BV) group: medium–large varices 
requiring banding at endoscopy. Figure 1 illustrates 
the number of episodes in each group. 
 
Age Distribution 
75.3% (n=73) of episodes were in patients 
between 50 -69 years of age (Figure 2) 
 
 
 
 
 
Gender distribution  
71.1% (n=69) of episodes studied involved 
males (figure 3). This gender distribution was 
similar throughout the three groups. 
 
Table 1: Population Demographics 
 
 
 
VARIABLE 
MEAN (± SD) OR 
NUMBER (%) 
Age (years) 60.8±9.3 
Gender (male) 69 (71.1%) 
Gender (female) 28 (28.9%) 
Aetiology of cirrhosis   
   AICAH 2 (2.1%) 
   AIH 1 (1.0%) 
   ALD 25 (25.8%) 
   Cryptogenic 10 (10.3%) 
   HBV 8 (8.2%) 
   HCV 15 (15.5%) 
   HCV/HBV 1 (1.0%) 
   NASH 28 (28.9%) 
   PBC 1 (1.0%) 
   PCLD 2 (2.1%) 
   PSC 2 (2.1%) 
   Schistosomiasis 1 (1.0%) 
   Wilson's 1 (1.0%) 
No varices on endoscopy 42 (43.3%) 
Varices on endoscopy 55 (56.7%) 
Grade of varices   
   Small varices 29 (52.7%) 
   Moderate varices 21 (38.2%) 
   Large varices 5 (9.1%) 
Treatment of varices   
    Varices not banded 28 (50.9%) 
    Varices banded x1 24 (43.6%) 
    Varices banded x2 3 (5.5%) 
Spleen size (cm) 13.3±2.3 
Splenomegaly 87 (89.6%) 
Child score 5 83 (85.6%) 
Child score 6 14 (14.4%) 
Platelet count x109/L  147.8±65.5 
Platelet count <150 
x109/L  48 (50.5%) 
HCC comorbid patients 12 (12.4%) 
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Table 2: Child-Pugh classification used in the study 
 
CHILD SCORE 1 2 3 
Encephalopathy Absent Mild (1,2) Severe (3,4) 
Ascites Absent Easy to Rx Difficult to Rx 
Bilirubin <4   34-51 >51 
Albumin >35 28-35 <28 
INR <1.3 1.3-1.5 >1.5 
 
 
Figure 1: The 97 episodes were divided into 3 groups depending on gastroscopy findings- absent varices (AV) 
group, small varices (SV) group and banded varices (BV) group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Age distribution. N=97 
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Figure 3: Gender distribution. N=97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Proportion of the total population with spleen size <12cm vs proportion with splenomegaly. N= 97 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Spleen size across the three groups; absent varices (AV) group, small varices (SV) group and banded 
varices (BV) group 
 
GROUP Normal Spleen Spleen >12cm % Splenomegaly 
AV group 2 40 95.2% 
SV group 8 20 71.4% 
BV group 0 27 100% 
 
 
 
 
 
69
28
Total Males
Total Females
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Table 4: ANOVA results comparing spleen size between the groups 
 
  AV group SV group BV group 
Mean 12.8 12.9 14.2 
95% confidence interval for Mean 12.09-13.48 12.06-13.76 13.31-15.04 
Standard deviation 1.64 2.85 2.4 
High 16.5 19 20.2 
Low 8 4.4 12 
Median 12 12 13 
Absolute Average deviation from 
Median 1.05 2.02 1.99 
 
 
Table 5: Platelet count across the three groups 
GROUP Platelets (109/L) <150 Platelets (109/L) >150 
% with 
thrombocytopenia 
AV 16 26 38.1% 
SV 13 15 46.4% 
BV 18 9 66.7% 
 
 
Table 6: ANOVA results comparing platelet count across the three groups 
  AV group SV group BV group 
Mean 169 143 120 
95% confidence interval for Mean 150-188 119-167 96-144 
Standard deviation 72 58 52 
High 380 321 243 
Low 70 37 48 
Median 158 141 119 
Absolute Average deviation from Median 47.4 43.5 45 
 
 
Spleen size (cm)  
89.6% (n=87) of the population studied had a 
spleen size >12cm as seen in figure 4. Interestingly 
23.8% (n=10) of AV group patients had spleens 
larger than 14 cm. On the other hand, none of the 
patients in BV group had a normal sized spleen 
(<12 cm) (table 3). 
Statistical analysis using ANOVA showed 
that spleen size difference between the 3 groups 
was statistically significant (p= 0.035) (table 4). 
 
Platelet count: Units x109/L 
In BV group, 66.7% (n=18) of patients had a 
platelet count <150 x109/L whereas in AV group 
61.9% (n=26) of patients had a platelet count > 150 
x109/L (table 5). 
Statistical analysis using ANOVA showed 
that platelet count differences between the 3 groups 
was statistically significant (p=0.008) (table 6).  
 
Discussion 
Several recent studies have explored possible 
non-invasive predictors of the presence and/or 
severity of oesophageal varices in cirrhotics 
including such indices as spleen size, platelet count, 
spleen stiffness, liver stiffness, liver volume and 
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serum albumin level.10-11,5 Spleen size and platelet 
count are indices which are readily available after 
initial workup of patients with chronic liver disease 
and were thus selected in this study for further 
evaluation. Studies have shown that as cirrhosis 
progresses spleen size tends to increase and platelet 
count tends to decrease.6 The aim of this study was 
to assess whether one could predict which patients 
would have oesophageal varices requiring treatment 
before performing endoscopy and therefore which 
patients can safely avoid such invasive monitoring.  
In this study 66.7% of BV group had platelet counts 
below 150 x109/L as opposed to 38.1% of AV 
group patients and this result was statistically 
significant. There was still however considerable 
overlap between the 2 groups such that 33.3% (n=9) 
of BV group patients had platelet counts above 150 
x109/L. Platelet counts on their own therefore 
cannot be used to predict the presence of varices in 
cirrhotic patients. In the case of spleen size the 
differences between groups were again statistically 
different and the overlap between the groups was 
less marked. A possible inference from the results 
obtained would be that with spleen size of <12 cm 
varices requiring banding would not be found. 
However, only 10.3% (n=10) of the population 
studied had a spleen size within normal limits, and 
out of these, 8 episodes had small oesophageal 
varices (SV group) which would still require 
treatment with non-selective beta blockers. 
In recently published guidelines 2 
recommendations were made for which cirrhotic 
patients could safely avoid screening at endoscopy. 
These guidelines stated that patients with a liver 
stiffness <20 kPa and with a platelet count >150 
x109/L have a very low risk of having varices 
requiring treatment, and can avoid screening 
endoscopy. Liver stiffness measurement was not 
considered in this study as this modality has only 
recently been introduced in Malta and is subject to 
numerous variables such as obesity, elevated ALT 
levels and liver venous or biliary congestion.12  
The main limitation of our study was that the 
diagnosis of cirrhosis was based on imaging studies 
rather than liver biopsies. Liver biopsies are 
considered invasive and often avoided clinically. In 
future, similar studies should also include liver 
stiffness measurements in the diagnosis of cirrhosis. 
Another limitation of our study was that patients 
with different aetiologies of cirrhosis were 
recruited. Considering cirrhotic patients with a 
single aetiology may produce more robust 
conclusions. Furthermore, when collecting data on 
spleen size US, CT and MRI modalities were 
referenced depending on which imaging study was 
performed closest to the date of endoscopy. More 
accurate measurements would have been obtained 
had all spleen size measurements been calculated 
using MRI13 however since data was collected 
retrospectively this was not possible. At the start of 
the study several inclusion and exclusion criteria 
were laid out before selecting the population to be 
studied to improve validity of the results obtained. 
One limitation of the study however was that not all 
variables that may affect spleen size and platelet 
count were taken into consideration. 
In conclusion, despite the relatively small size 
of our study the results were statistically significant 
and it is unlikely that more patients would have 
resulted in a different outcome. Having said this, 
the study did not yield any new recommendations to 
alter existing clinical practice. 
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